Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Advantest Shares Hit Record High on Strong AI-Driven Earnings and Nvidia Demand 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Google Halts UK YouTube TV Measurement Service After Legal Action 
LONDON, May 23, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs, announced today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the Jefferies 2017 Global Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Jefferies Healthcare Conference
Date: June 8, 2017
Time: 11:30 AM EDT
Location: New York, NY
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||||
| Aubrey Powell / James White | ||||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||||
| ICR, Inc. (US Media and Investor enquiries) | ||||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
